Phio Pharmaceuticals develops cancer treatments that use its INTASYL RNA technology to help the immune system attack tumors. It last closed at $0.66 on Nov 20, down 8.25% on the day. The next earnings report for PHIO is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, PHIO reported EPS of -$0.36. Over its last 8 reports the stock moved an average of 3.4% the session after earnings. Over the last 12 months PHIO insiders bought $140K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is PHIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PHIO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on PHIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
PHIO · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 24% below its 20 day and 38% below its 50 day average. It is 63% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $0.64, and the nearest resistance the Pivot at $0.68.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.6%/day
Key levels
$1.8852 week high+184.8%
$1.07200 day average+62.1%
$0.99100 day average+50.0%
$0.9150 day average+37.9%
$0.86Swing high (Nov 11)+30.3%
$0.8120 day average+22.7%
$0.72Pivot R1+9.1%
$0.68Pivot+3.0%
$0.66Last close
$0.6452 week low−3.0%
$0.62Pivot S1−6.1%
Indicators
RSI (14)
22.61
Oversold below 30
Oversold
MACD
-0.06
Below its signal line
Bearish
Stochastic
6.7
Near the bottom of its range
Oversold
ADX (14)
23.9
Weak trend
Williams %R
-94.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-171.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−18.1%
Change over 10 sessions
Bearish
ATR (14)
$0.06
Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 20.0%/day
Key levels
$1.8852 week high+184.8%
$1.07200 day average+62.1%
$0.99100 day average+50.0%
$0.9150 day average+37.9%
$0.86Swing high (Nov 11)+30.3%
$0.8120 day average+22.7%
$0.72Pivot R1+9.1%
$0.68Pivot+3.0%
$0.66Last close
$0.6452 week low−3.0%
$0.62Pivot S1−6.1%
Indicators
RSI (14)
24.98
Oversold below 30
Oversold
MACD
-0.11
Below its signal line
Bearish
Stochastic
5.8
Near the bottom of its range
Oversold
ADX (14)
22.0
Weak trend
Williams %R
-97.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-207.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−36.3%
Change over 10 sessions
Bearish
ATR (14)
$0.13
Typical daily range, 20.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PHIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PHIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow PHIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for PHIOHow many large options trades hit PHIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in PHIO in the last 90 days.
From SEC Form 4 filings by PHIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHIO is in one of them and how their past PHIO trades turned out.
Phio Pharmaceuticals is a clinical stage biopharmaceutical company based in King of Prussia, Pennsylvania. It is developing cancer treatments based on its INTASYL small interfering RNA technology, which is designed to silence proteins that reduce the immune system's ability to attack tumors. Its lead candidate, PH-762, is being tested in a clinical trial in patients with skin cancers, including cutaneous squamous cell carcinoma and melanoma. The therapies are designed for patients with cancer and are given by injection directly into tumors.